Drug intelligence / Profile preview

Lodrane 24D

Development stage
Phase 3
Lead developer
Elite Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

**Lodrane 24D** is an extended-release combination pharmaceutical product containing **brompheniramine maleate** (12 mg), an antihistamine, and **pseudoephedrine sulfate** (or HCl), a nasal decongestant, formulated for once-daily dosing. It provides symptomatic relief from nasal congestion, runny nose, sneezing, itchy/watery eyes, and other upper respiratory symptoms associated with **allergic rhinitis**, **common cold**, **hay fever**, **seasonal/perennial allergies**, **vasomotor rhinitis**, and related conditions like sinusitis or flu. Brompheniramine blocks histamine H1 receptors to reduce allergic responses, while pseudoephedrine acts as an alpha-adrenergic agonist to vasoconstrict nasal blood vessels and decrease congestion. Developed using Elite Pharmaceuticals' controlled-release technology (e.g., bead systems for sustained delivery over 24 hours), it was launched around 2006 via partnerships like ECR Pharmaceuticals (Hi-Tech Pharmacal subsidiary) and is available as prescription/OTC capsules.[1][3][6][7][8][9]

Brand names
Lodrane 24DLodrane24DLodrane-24D
Other names
Lodrane 24 D ER CapsuleLodrane24 D ER CapsuleLodrane-24 D ER Capsule
02

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Lodrane 24D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lodrane 24D.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call